ACADIA Pharmaceuticals Inc. (ACAD)

29.61
NASDAQ : Health Technology
Prev Close 29.02
Day Low/High 29.22 / 29.86
52 Wk Low/High 12.86 / 30.38
Avg Volume 1.23M
Exchange NASDAQ
Shares Outstanding 144.49M
Market Cap 4.19B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
Today's Water-Logged And Getting Wetter Stock: ACADIA Pharmaceuticals (ACAD)

Today's Water-Logged And Getting Wetter Stock: ACADIA Pharmaceuticals (ACAD)

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

Analysts' Actions -- Intel, Texas Instruments and Viacom

Analysts' Actions -- Intel, Texas Instruments and Viacom

Here are Friday's top research calls, including downgrades of Intel and Texas Insturments

ACADIA Pharmaceuticals Reports Second Quarter 2015 Financial Results

ACADIA Pharmaceuticals Reports Second Quarter 2015 Financial Results

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous...

ACADIA Pharmaceuticals Announces Publication Of Data From Its -015 Open Label Safety Study In Parkinson's Disease Psychosis In The Journal Of The American Medical Directors Association

ACADIA Pharmaceuticals Announces Publication Of Data From Its -015 Open Label Safety Study In Parkinson's Disease Psychosis In The Journal Of The American Medical Directors Association

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous...

ACADIA Pharmaceuticals Announces Senior Management Appointments In Manufacturing, Quality, Compliance, Access And Reimbursement And Business Development

ACADIA Pharmaceuticals Announces Senior Management Appointments In Manufacturing, Quality, Compliance, Access And Reimbursement And Business Development

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous...

ACADIA Pharmaceuticals To Announce Second Quarter Financial Results On August 6, 2015

ACADIA Pharmaceuticals To Announce Second Quarter Financial Results On August 6, 2015

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous...

ACADIA Pharmaceuticals (ACAD) Strong On High Relative Volume Today

ACADIA Pharmaceuticals (ACAD) Strong On High Relative Volume Today

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a strong on high relative volume candidate

ACADIA Pharmaceuticals To Present At The JMP Securities Life Sciences Conference On June 24, 2015

ACADIA Pharmaceuticals To Present At The JMP Securities Life Sciences Conference On June 24, 2015

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it...

ACADIA Pharmaceuticals Presents Integrated Data From Its Phase III Program With NUPLAZID™ (Pimavanserin) For Parkinson's Disease Psychosis At The 19th International Congress Of Parkinson's Disease And Movement Disorders

ACADIA Pharmaceuticals Presents Integrated Data From Its Phase III Program With NUPLAZID™ (Pimavanserin) For Parkinson's Disease Psychosis At The 19th International Congress Of Parkinson's Disease And Movement Disorders

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the...

ACADIA Pharmaceuticals To Present At The Jefferies 2015 Healthcare Conference On June 2, 2015

ACADIA Pharmaceuticals To Present At The Jefferies 2015 Healthcare Conference On June 2, 2015

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it...

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Post-Market Leader Stock

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a post-market leader candidate

ACADIA Pharmaceuticals Reports First Quarter 2015 Financial Results

ACADIA Pharmaceuticals Reports First Quarter 2015 Financial Results

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous...

ACADIA Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference On May 13, 2015

ACADIA Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference On May 13, 2015

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it...

ACADIA Pharmaceuticals To Announce First Quarter Financial Results On May 7, 2015

ACADIA Pharmaceuticals To Announce First Quarter Financial Results On May 7, 2015

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous...

SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notify Investors Of Class Action Involving Acadia Pharmaceuticals Inc. And A Lead Plaintiff Deadline Of May 12, 2015

SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notify Investors Of Class Action Involving Acadia Pharmaceuticals Inc. And A Lead Plaintiff Deadline Of May 12, 2015

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased ACADIA Pharmaceuticals Inc.

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In ACADIA Pharmaceuticals Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In ACADIA Pharmaceuticals Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Acadia Pharmaceuticals Inc. Of Pendency Of Class Action Lawsuit And A Lead Plaintiff Deadline Of May 12, 2015

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Acadia Pharmaceuticals Inc. Of Pendency Of Class Action Lawsuit And A Lead Plaintiff Deadline Of May 12, 2015

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired common shares of Acadia Pharmaceuticals Inc.

'Mad Money' Lightning Round: Buy, Buy, Buy Whole Foods Markets

'Mad Money' Lightning Round: Buy, Buy, Buy Whole Foods Markets

Cramer likes Acadia Pharmaceuticals and prefers Schlumberger over U.S. Silica Holdings.

Jim Cramer's 'Mad Money' Recap: 6 Positive Things You Should Keep in Focus

Jim Cramer's 'Mad Money' Recap: 6 Positive Things You Should Keep in Focus

From earnings to activist investors, Cramer said investors need to focus on the good things now happening in the markets.

ACADIA Pharmaceuticals To Present At The 14th Annual Needham Healthcare Conference On April 14, 2015

ACADIA Pharmaceuticals To Present At The 14th Annual Needham Healthcare Conference On April 14, 2015

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it...

ACADIA Pharmaceuticals Appoints Daniel Soland To Board Of Directors

ACADIA Pharmaceuticals Appoints Daniel Soland To Board Of Directors

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous...

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In ACADIA Pharmaceuticals Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In ACADIA Pharmaceuticals Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf...

ACADIA Pharmaceuticals Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

ACADIA Pharmaceuticals Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit...

'Mad Money' Lightning Round: Dave and Buster's Is Too Risky for Me

'Mad Money' Lightning Round: Dave and Buster's Is Too Risky for Me

Cramer is staying away from Acadia Pharmaceuticals and thinks Bluebird Bio is overheating.

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Cramer will be listening and learning next week as Foot Locker, FedEx, Oracle and Darden report.

Buyers Get Back to Big-Caps

Market shows some love to overlooked groups.

Stocks Bounce Back After Two-Day Selloff as Fed Anxiety Eases

Stocks Bounce Back After Two-Day Selloff as Fed Anxiety Eases

The Dow climbed 260 points on Thursday, shooting higher on a rally among major U.S. banks.

TheStreet Quant Rating: D (Sell)